Yipinhong Pharmacy logo

Yipinhong Pharmacy

Asia, Guangdong, China, Guangzhou

Description

Yipinhong Pharmacy is a pharmaceutical research and development, production, sales for the core business of modern pharmaceutical company.

Investor Profile

Yipinhong Pharmacy has backed more than 1 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 0 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series C rounds (top funding stages).
  • Majority of deals are located in United States.
  • Strong thematic focus on Biotechnology, Clinical Trials, Health Care.

Stage Focus

  • Series C (100%)

Country Focus

  • United States (100%)

Industry Focus

  • Biotechnology
  • Clinical Trials
  • Health Care
  • Pharmaceutical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Yipinhong Pharmacy frequently co-invest with?

Gilead Sciences
North America, California, United States, Foster City
Co-Investments: 1
AIG Investments
North America, New York, United States, New York
Co-Investments: 1
Quark Venture
North America, British Columbia, Canada, Vancouver
Co-Investments: 1
Mass General Brigham Ventures
North America, Massachusetts, United States, Cambridge
Co-Investments: 1
Polaris Partners
North America, Massachusetts, United States, Boston
Co-Investments: 1
ImpactAssets
North America, Maryland, United States, Bethesda
Co-Investments: 1
Limitless Ventures
North America, Utah, United States, South Jordan
Co-Investments: 1
HOPU Investment Management Company
Asia, Hebei, China, Xicheng
Co-Investments: 1
THE CATALYTIC IMPACT FOUNDATION (CIF)
North America, New York, United States, New York
Co-Investments: 1
Invus
North America, New York, United States, New York
Co-Investments: 1

What are some of recent deals done by Yipinhong Pharmacy?

Lyndra Therapeutics

Watertown, Massachusetts, United States

Lyndra Therepeutics creates therapies for long-term drug release in an oral dose form.

BiotechnologyClinical TrialsHealth CarePharmaceutical
Series CJun 24, 2021
Amount Raised: $60,500,000